Plain-English translation of NCT05092984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research is testing whether , a medication commonly used to treat heart problems, could also help people with rheumatoid arthritis (RA) who aren't responding well to their current treatments. The medication has anti-inflammatory properties that early research suggests might reduce joint inflammation and protect the heart. Researchers want to see if this treatment could be a helpful addition for people with hard-to-control RA.
People with rheumatoid arthritis face higher risks of heart disease and death compared to the general population, mainly because of ongoing inflammation in their bodies. Since this medication has helped heart patients in other conditions, researchers believe it may both reduce RA inflammation and provide heart protection for people with this disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication (or placebo) daily as part of this research. You'll visit the study clinic for check-ups to monitor how you're doing, including blood tests to check your kidney function and potassium levels, since the medication affects these. The study lasts 6 months, and researchers will track whether your joint symptoms improve and whether the treatment is safe for you.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
France